SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The community is debating a campaign promise to issue a $5,000 dividend to every U.S. adult if Republicans win the midterms, with many traders criticizing it as election bribery and an unsustainable fiscal policy. Supporters and detractors continue to clash over the proposal's potential impact on the national debt and the candidate's track record on previous financial commitments.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple shares are reacting to the company's product launch event, which featured the debut of the foldable iPhone Duo, alongside new iPhone 18 Pro models and updated wearable devices. Traders and investors are divided on the hardware, with debate centering on whether the high-priced foldable device will drive a new revenue supercycle or fail to attract mass-market adoption.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment shares are receiving attention as traders evaluate a strong fiscal first-quarter earnings report that featured a revenue beat and record funded backlog. While some investors remain cautious regarding the impact of government budget timing on forward guidance and estimate trends, others are bullish on the company's expansion into directed-energy weapons and counter-drone systems.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending due to the company reaching a key enrollment milestone for its Phase 3 clinical trial of HLP003, with investors reacting to the maintained timeline for topline data in late 2026. The stock is also receiving attention from analysts who maintain bullish price targets, citing its Breakthrough Therapy Designation and potential role in the evolving psychedelic neuropsychiatry sector.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending following news that it will be removed from the S&P 100 index, a development that has intensified debates among investors over the company's long-term turnaround prospects versus concerns about ongoing market share losses and brand management. The community remains deeply divided, with some traders viewing the current depressed valuation as a deep-value buying opportunity while others express skepticism, citing concerns about recent leadership changes and the sustainability of sales performance.

American Eagle Outfitters, Inc. operates retail stores and e-commerce channels offering apparel, accessories, and personal care products under the American Eagle and Aerie brands. It also operates the OFFL/NE by Aerie, Todd Snyder, and Unsubscribed brands. The firm operates stores in the United States, Canada, and Mexico and sells its products through international license partners. The company was founded in 1977 and is headquartered in Pittsburgh, PA.

American Eagle Outfitters Inc.

American Eagle Outfitters, Inc.

American Eagle shares trended lower following an earnings release that disappointed the market, as investors discounted strong results driven by non-recurring tariff refunds and expressed concerns over flat same-store sales guidance for the core brand. While traders debated whether the sell-off was an overreaction given the company's profitability and Aerie segment momentum, many remain skeptical of the stock's near-term recovery prospects.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven shares are reacting to the company's disclosure that the FDA has ordered a pause in enrollment for the BHV7000-303 epilepsy study, though dosing continues and the data readout remains on schedule for late 2026. While some investors view the pullback as a buying opportunity, others are expressing concern over the regulatory setback.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The conversation is dominated by reactions to President Trump's campaign proposal of a $5,000 dividend for voters, which many traders are debating as a potential inflationary catalyst or political bribe. This discussion is intertwined with broader anxiety surrounding upcoming inflation data (PPI and CPI), rising crude oil prices, and climbing Treasury yields, leading to a cautious, split market sentiment.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is trending primarily due to the announcement of a definitive agreement to acquire Ratel Robotics for up to $224 million, a move aimed at expanding the company's ground-based defense technology and drone swarm coordination capabilities. While some market participants anticipate this acquisition will drive significant momentum and long-term growth, others express caution regarding potential share dilution and future cash burn.

Polygon

Polygon is trending as investors react to a significant acquisition-led strategy shift, with the project moving to establish a U.S.-regulated payment infrastructure and host institutional-grade real-world asset tokenization. While some participants express frustration over price performance relative to other assets, others are building positions in anticipation of these developments and upcoming regulatory milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PRAX  This graphic shows PRAX&#39;s forecasted peak sales projections for their products that have passed or are undergoing ph3 trials.   You can see these add up to $20 billion/yr.  If PRAX were to be acquired, Google AI says you can estimate the acquisition price as follows:   
 
To estimate a central nervous system (CNS) biotech company&#39;s acquisition price, multiply its projected peak sales by a valuation multiple of 3.5x to 5.5x for Phase 3 assets (or 2.0x to 3.5x if still in early Phase 3 with high regulatory risk), then adjust for net cash and probability of success.  
 
You do the math.

John

StockTwits Web

Praxis Precision Medicines Inc

  This graphic shows PRAX's forecasted peak sales projections for their products that have passed or are undergoing ph3 trials.   You can see these add up to $20 billion/yr.  If PRAX were to be acquired, Google AI says you can estimate the acquisition price as follows:   
 
To estimate a central nervous system (CNS) biotech company's acquisition price, multiply its projected peak sales by a valuation multiple of 3.5x to 5.5x for Phase 3 assets (or 2.0x to 3.5x if still in early Phase 3 with high regulatory risk), then adjust for net cash and probability of success.  
 
You do the math.

Trainguy1

@Trainguy1 well I love this company and I love the way you think about it but I don&#39;t see anyody dropping 50b for a company with no approved products. It basically would mean certain bankruptcy if they don&#39;t make it through approval. If I&#39;m not mistaken the highest price ever paid for a phase 3 company with no approvals is about $21 billion. Ive a hunch no sale until at least one approval and then 50 billion is not out of the ballpark. That being said I hope you are right and I am wrong. Good luck to us.

StockTwits For Android 

 well I love this company and I love the way you think about it but I don't see anyody dropping 50b for a company with no approved products. It basically would mean certain bankruptcy if they don't make it through approval. If I'm not mistaken the highest price ever paid for a phase 3 company with no approvals is about $21 billion. Ive a hunch no sale until at least one approval and then 50 billion is not out of the ballpark. That being said I hope you are right and I am wrong. Good luck to us.

Fred Merrz

I noticed Vormatrigine’s ph2/3 trial primary end point was missed, but the secondary end point was met (a higher dose was delivered for the secondary end point) and the OLE continues.  Praxis is considering their options.